Seroquel XR in Schizophrenia Relapse Prevention

November 16, 2010 updated by: AstraZeneca
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Anticipated)

1600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Hungary
      • Baja, Hungary
        • Research Site
      • Barcs, Hungary
        • Research Site
      • Budapest, Hungary
        • Research Site
      • Cegled, Hungary
        • Research Site
      • Debrecen, Hungary
        • Research Site
      • Dombovar, Hungary
        • Research Site
      • Dunaujvaros, Hungary
        • Research Site
      • Eger, Hungary
        • Research Site
      • Egerszalok, Hungary
        • Research Site
      • Emod, Hungary
        • Research Site
      • Erd, Hungary
        • Research Site
      • Esztergom, Hungary
        • Research Site
      • Godollo, Hungary
        • Research Site
      • Gyongyos, Hungary
        • Research Site
      • Gyor, Hungary
        • Research Site
      • Gyula, Hungary
        • Research Site
      • Heves, Hungary
        • Research Site
      • Hodmezovasarhely, Hungary
        • Research Site
      • Janoshalma, Hungary
        • Research Site
      • Jaszbereny, Hungary
        • Research Site
      • Kalocsa, Hungary
        • Research Site
      • Kecskemet, Hungary
        • Research Site
      • Ketegyhaza, Hungary
        • Research Site
      • Kiskunhalas, Hungary
        • Research Site
      • Kistokaj, Hungary
        • Research Site
      • Miskolc, Hungary
        • Research Site
      • Nagyatad, Hungary
        • Research Site
      • Nagykallo, Hungary
        • Research Site
      • Nagykanizsa, Hungary
        • Research Site
      • Nagykoros, Hungary
        • Research Site
      • Oroshaza, Hungary
        • Research Site
      • Pecs, Hungary
        • Research Site
      • Pomaz, Hungary
        • Research Site
      • Satoraljaujhely, Hungary
        • Research Site
      • Soltvadkert, Hungary
        • Research Site
      • Sopron, Hungary
        • Research Site
      • Sumeg, Hungary
        • Research Site
      • Szeged, Hungary
        • Research Site
      • Szeghalom, Hungary
        • Research Site
      • Szekesfehervar, Hungary
        • Research Site
      • Szekszard, Hungary
        • Research Site
      • Szentes, Hungary
        • Research Site
      • Szigetszentmiklos, Hungary
        • Research Site
      • Szigetvar, Hungary
        • Research Site
      • Szolnok, Hungary
        • Research Site
      • Szombathely, Hungary
        • Research Site
      • Tatabanya, Hungary
        • Research Site
      • Veszprem, Hungary
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Psychiatric outpatient clinics

Description

Inclusion Criteria:

  • Schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month

Exclusion Criteria:

  • Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
1
Schizophrenic outpatients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Rate of patients remained relapse free after 6 months of treatment

Secondary Outcome Measures

Outcome Measure
Adherence rate of patients
Quality of Life (QoL )

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

  • Principal Investigator: Attila Németh, National Psychiatric Centre
  • Study Chair: Lilla Szabó, AstraZeneca Hungary MC
  • Study Director: Tamás Bábel, AstraZeneca Hungary MC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2009

Primary Completion (Actual)

July 1, 2010

Study Completion (Actual)

July 1, 2010

Study Registration Dates

First Submitted

October 1, 2009

First Submitted That Met QC Criteria

October 6, 2009

First Posted (Estimate)

October 7, 2009

Study Record Updates

Last Update Posted (Estimate)

November 17, 2010

Last Update Submitted That Met QC Criteria

November 16, 2010

Last Verified

November 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIS-NHU-SER-2009/1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe